Breaking Peptide News: FDA Panel Votes on BPC-157, TB-500, KPV, MOTS-c

FDA / PCAC — official records & coverage — Breaking Peptide News: FDA Panel Votes on BPC-157, TB-500, KPV, MOTS-c

Channel: Barrick Health · Our label: Government proceedings and coverage of them · Source: youtube.com/watch?v=qiQaJt_H6m8

What this video covers

All right, the verdict is in and I’ve got the breakdown, at least the first half of the verdict. Peptide news is breaking and some of this stuff is surprising. The FDA’s own scientists recommended rejecting all seven peptides. Let’s look at what the committee actually decided.

Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.

Key points, in the speaker’s own framing

• The FDA’s own scientists recommended rejecting all seven peptides.
• Naturally occurring peptide peptides can lack the patent protection needed to justify a billion dollar drug development program.
• That leaves compounds like MOTS-c trapped between two systems.
• Regulators seek evidence normally financed through a protected commercial pathway, while the economics needed to produce that evidence may never exist.
• Tomorrow, Epitalon, Dihexa, and Semax get their day in court.
• Semax is up first, and it carries the strongest evidence file of all seven.

Read next

• BPC-157 — compound page
• TB-500 — compound page
• MOTS-c — compound page
• Epitalon — compound page
• Semax — compound page
• KPV — compound page
• Dihexa — more videos
• Wolverine stack
• All videos from this channel

Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.